Partner Headlines - AMRN

  1. Amarin Announces Agreement to Purchase $16.2M of Its Existing ...

    Benzinga
  2. Amarin Popped Ahead Of Press Release In Friday's After-Hours ...

    Benzinga
  3. Amarin Popped Amid Press Release In Friday's After-Hours Session

    Benzinga
  4. EXCLUSIVE: Expect Amarin FAQ Shortly

    Benzinga
  5. EPA Therapy Added to Statin Therapy Showed Coronary Plaque Regression ...

    Benzinga
  6. UPDATE: WHat Amarin Would Need TO Disclose To Ensure Non-Misleading ...

    Benzinga
  7. First Amendment Decision a Win for Amarin and Physician Plaintiffs

    Benzinga
  8. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  9. Week Concludes With S&P 500 Below 2,000; Dow Below 17,000

    Benzinga
  10. Dow Falls Over 100 Points; Ulta Salon Shares Jump After Earnings ...

    Benzinga
  11. Conversant Shares Rise On Acquisition News; Health Care REIT ...

    Benzinga
  12. Markets Drop; Darden Adjusted Profit Beats Street View

    Benzinga
  13. Morning Market Losers

    Benzinga
  14. Amarin Moves Higher On Speculation Of Special Protocol Assessment

    Benzinga
  15. Top Performing Industries For June 12, 2014

    Benzinga
  16. FDA Approvals And Changes For The Week Ending February 14, 2 ...

    Benzinga
  17. Amarin Announces FDA DMEP Does Not Plan to Re-instate ANCHOR ...

    Benzinga
  18. Benzinga's Top #PreMarket Losers

    Benzinga
  19. Amarin Announces FDA Review Division Response on ANCHOR SPA Agreement ...

    Benzinga
  20. FDA Delays Decision on Amarin's Vascepa Drug

    Benzinga
  21. Amarin Receives FDA Notification That Action on ANCHOR sNDA Review ...

    Benzinga
  22. Amarin's Vascepa: Too Limited A Market Or FDA Blunder?

    Benzinga
  23. Amarin Announces Notification of Patent Allowances Related to ...

    Benzinga
  24. New Statin Rules: Which Drugmakers Had Ties?

    YCharts
  25. Is Amarin’s Fish Oil Blockbuster Dream Kaput?

    YCharts
  26. UPDATE: Citigroup Upgrades Amarin on Valuation

    Benzinga
  27. Benzinga's Top Upgrades

    Benzinga
  28. Aegis Capital Corp. Reiterates on Amarin Corporation plc After ...

    Benzinga
  29. Market Wrap For Thursday, October 17: S&P Record High On Debt ...

    Benzinga
  30. Mid-Day Market Update: SanDisk Surges On Upbeat Results; IBM ...

    Benzinga
  31. Mid-Morning Market Update: Markets Open Lower; Goldman Sachs ...

    Benzinga
  32. Stocks Hitting 52-Week Lows

    Benzinga
  33. UPDATE: Aegis Capital Downgrades Amarin Following Negative Panel ...

    Benzinga
  34. Benzinga's Top Pre-Market Losers

    Benzinga
  35. Amarin Announces Negative FDA Advisory Committee Outcome for ...

    Benzinga
  36. Amarin Halted Ahead of FDA Advisory Committee to Review sNDA ...

    Benzinga
  37. Aegis Says FDA's Outlook 'Not As Negative As People Think' on ...

    Benzinga
  38. Aegis Capital Reiterates Buy on Amarin Corporation Following ...

    Benzinga
  39. Jefferies Reiterates Buy on Amarin Corporation on Continued Positive ...

    Benzinga
  40. Goldman Sachs Reiterates Neutral on Amarin Ahead of Advisory ...

    Benzinga
  41. Amarin Shares Up 5% as FDA Says October 16th Advisory Committee ...

    Benzinga
  42. Enrollment in Amarin REDUCE-IT Cardiovascular Outcomes Study ...

    Benzinga
  43. Amarin Reports 30th Patent for Vascepa

    Benzinga
  44. Amarin Submits Supplemental NDA for Novasep as Fourth Vascepa ...

    Benzinga
  45. UPDATE: Citigroup Raises PT on Amarin Following Lighter 2Q13 ...

    Benzinga
  46. UPDATE: Jefferies Lowers PT on Amarin on Continued ANCHOR Partnership ...

    Benzinga
  47. Amarin Announces USPTO Allowance for Application 13/614,129 Related ...

    Benzinga
  48. Amarin Announces Patent Allowance Related to Vascepa and FDA ...

    Benzinga
  49. Weekly Guru Bargains Highlights: PANL, THRX, ZNGA, LORL, AMRN

    GuruFocus
  50. Benzinga's Top Pre-Market Gainers

    Benzinga
  51. Amarin Completes Dosing in a Fixed-Dose Combination Study With ...

    Benzinga
  52. Amarin Closes Dosing in Fixed-Dose Combination Study with Vascepa

    Benzinga
  53. FDA's Orange Book Doesn't Include Amarin's Vascepa NCE Status ...

    Benzinga
  54. Benzinga's Top Pre-Market Gainers

    Benzinga
  55. Amarin Receives Patent Allowance for Application 13/623,450 Related ...

    Benzinga
  56. Amarin Announces David Stack Appointed to Board of Directors

    Benzinga
  57. Amarin Spikes Lower

    Benzinga
  58. UDPATE: Aegis Capital Raises PT on Amarin to $35

    Benzinga
  59. Citigroup Reiterates Buy Rating, $20 PT on Amarin Corporation

    Benzinga
  60. Benzinga's Top Pre-Market Losers

    Benzinga
  61. UPDATE: Citigroup Initiates Amarin at Buy on Vascepa Overhang ...

    Benzinga
  62. Benzinga's Top Pre-Market Gainers

    Benzinga
  63. Amarin Awarded Patent 8,318,715 for Vascepa by USPTO

    Benzinga
  64. Amarin Announces USPTO has Published Notification of Notice of ...

    Benzinga
  65. A Peek Into The Market Before The Trading Starts

    Benzinga
  66. Amarin Announces US Patent 8,314,086 Award for Vascepa

    Benzinga
  67. Mid-Morning Market Update: Markets Rallying; J.C. Penney Misses ...

    Benzinga
  68. Amarin Awarded US Patent 8,298,554 Issuance for Vascepa

    Benzinga
  69. UPDATE: Wedbush Securities Downgrades Amarin Corporation to Neutral, ...

    Benzinga
  70. Benzinga's M&A Chatter for Tuesday September 11, 2012

    Benzinga
  71. Benzinga's M&A Chatter for Thursday September 6, 2012

    Benzinga
  72. Amarin Announces Notification of Patent Allowances for U.S. Applications ...

    Benzinga
  73. Amarin Announces Notification of Patent Allowance for Vascepa ...

    Benzinga
  74. Amarin Announces Additional Publication of MARINE Phase 3 Clinical ...

    Benzinga
  75. Health Care Sector Wrap

    FoxBusiness
  76. Benzinga's Top Pre-Market Gainers

    Benzinga
  77. Health Care Sector Wrap

    FoxBusiness
  78. Health Care Sector Wrap

    FoxBusiness
  79. Amarin Corporation (AMRN) Sees Spike in Option Activity with ...

    MarketIntelligenceCenter
  80. Amarin's

    IBD
  81. Facebook Inc. - Class A, Starbucks Among Stocks Down on High ...

    FoxBusiness
  82. Amarin Announces FDA Approval of Vascepa Capsules for the Reduction ...

    Benzinga
  83. Amarin and Horizon Pharma Higher Ahead of PDUFA Dates

    Benzinga
  84. Health Care Sector Wrap

    FoxBusiness
  85. Amarin Responds to Erroneous Website Posting

    Benzinga
  86. Biotechs With Upcoming PDUFA Dates

    Benzinga
  87. UPDATE: Aegis Capital Initiates Amarin Corporation with Buy, ...

    Benzinga
  88. New Annual Highs: AMRN, DIS, and NWS

    SchaeffersResearch
  89. Health Care Sector Wrap

    FoxBusiness
  90. Amarin (AMRN) Gains 10.5% As Company Appears Close to Winning ...

    MarketIntelligenceCenter
  91. Amarin Corporation plc, Loral Space & Communications Gapping ...

    FoxBusiness
  92. UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT ...

    Benzinga
  93. CF Industries Holdings, SBA Communications Corporation Included ...

    FoxBusiness
  94. AMR101 Phase 3 Study Data in Patients With Diabetes Mellitus ...

    Benzinga
  95. Amarin Corporation plc (AMRN) Sees Above Average Option Activity ...

    MarketIntelligenceCenter
  96. Earnings Scheduled For May 8

    Benzinga
  97. Amarin

    IBD
  98. Amarin (AMRN) Up 20% on Patent News, Analyst Commentary

    MarketIntelligenceCenter
  99. Amarin Up 7% After FDA Announces it Will Not Convene FDA Panel ...

    Benzinga
  100. AMRN said the FDA accepted a new drug for review, while OII updated ...

    SchaeffersResearch
Trading Center